When telephone lines go down, or Internet connections are lost, our communities temporarily come to a halt. What if something similar were found to be happening in Parkinson's? This is the focus of Dr. Schmitz and her team at the PDF Research Center at Columbia University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Is ?-synuclein rising to the surface as a diagnostic biomarker for Parkinson disease?
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
Neurology 2013 Oct;
Authors: William P Cheshire, Ronald F Pfeiffer
From the Department of Neurology (W.P.C.), Mayo Clinic, Jacksonville, FL; and Department of Neurology (R.F.P.), University of Tennessee Health Science Center, Memphis.
In his historic manuscript on the "shaking palsy," James Parkinson expressed the hope "that some remedial process may ere long be discovered, by which, at least, the progress of the disease may be stopped."(1) Realization of that hope will require not only the discovery of a treatment that can halt or slow the progression of Parkinson disease (PD), but also the identification of early, accurate, and accessible biomarkers, for by the time the cardinal clinical signs of bradykinesia, rigidity, tremor, and postural instability appear, substantial destruction of nigrostriatal dopaminergic neurons has already occurred.
PMID: 24089391 [PubMed - as supplied by publisher]